Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Hepatology2013Vol. 58(6), pp. 1941–1952
Citations Over TimeTop 1% of 2013 papers
Bart Staels, A. Rubenstrunk, Benoît Noël, Géraldine Rigou, Philippe Delataille, Lesley J. Millatt, Morgane Baron, Anthony Lucas, Anne Tailleux, Dean W. Hum, Vlad Ratziu, Bertrand Cariou, Rémy Hanf
Abstract
The dual PPAR-α/δ agonist, GFT505, is a promising liver-targeted drug for treatment of NAFLD/NASH. In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms.
Related Papers
- → Pathology of non‐alcoholic fatty liver disease(2017)326 cited
- → Weight Loss and Non-alcoholic Fatty Liver Disease: Falls In Gamma-Glutamyl Transferase Concentrations are Associated with Histologic Improvement(2006)217 cited
- → Procoagulant imbalance in patients with non-alcoholic fatty liver disease(2014)191 cited
- → Testosterone Replacement Ameliorates Nonalcoholic Fatty Liver Disease in Castrated Male Rats(2013)82 cited
- → Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)(2007)40 cited